ImmunityBio (IBRX) News Today → Millionaire investor and Republican donor makes surprising election prediction (From InvestorPlace) (Ad) Free IBRX Stock Alerts $8.63 +0.51 (+6.28%) (As of 05:51 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12 at 4:03 AM | americanbankingnews.comImmunityBio (NASDAQ:IBRX) Shares Gap Down to $8.06May 11 at 11:43 AM | finance.yahoo.comImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 10 at 11:02 AM | investorplace.comIBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | investorplace.comThe 3 Best Bargain Stocks to Buy in May 2024May 8, 2024 | benzinga.comLatest News for ImmunityBio Stock (NASDAQ:IBRX)May 7, 2024 | finance.yahoo.comImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®May 7, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Up to $7.81ImmunityBio (NASDAQ:IBRX) Shares Gap Up to $7.81May 6, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 12.6% ImmunityBio (NASDAQ:IBRX) Shares Down 12.6%May 6, 2024 | investorplace.comEven Worse than Gamestop? 3 Meme Stocks That Are Screaming SellsMay 3, 2024 | msn.comSerum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo TherapyMay 2, 2024 | businesswire.comImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer TypesMay 1, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 11.4%ImmunityBio (NASDAQ:IBRX) Shares Up 11.4%May 1, 2024 | theglobeandmail.comPromising Outlook as Biotech Sector Advances Cancer Treatments Amidst Rising DiagnosesApril 30, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 6.3% ImmunityBio (NASDAQ:IBRX) Stock Price Down 6.3%April 30, 2024 | businesswire.comImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological AssociationApril 29, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Sets New 12-Month High Following Analyst UpgradeImmunityBio (NASDAQ:IBRX) Sets New 12-Month High Following Analyst UpgradeApril 29, 2024 | marketbeat.comPiper Sandler Increases ImmunityBio (NASDAQ:IBRX) Price Target to $6.00Piper Sandler lifted their price objective on shares of ImmunityBio from $5.00 to $6.00 and gave the stock a "neutral" rating in a report on Monday.April 26, 2024 | msn.comWhat's Going On With ImmunityBio Stock?April 26, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Sees Strong Trading VolumeImmunityBio (NASDAQ:IBRX) Sees Strong Trading VolumeApril 25, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading 4.6% Higher ImmunityBio (NASDAQ:IBRX) Trading Up 4.6%April 25, 2024 | bizjournals.comFDA approves local company's bladder cancer drugApril 25, 2024 | businesswire.comImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung CancerApril 24, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - IBRXApril 24, 2024 | msn.comFDA approves bladder cancer treatment by Culver City companyApril 23, 2024 | finance.yahoo.comFDA Approves ImmunityBio's Bladder Cancer Drug, Stock RalliesApril 23, 2024 | seekingalpha.comImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential GainsApril 23, 2024 | marketbeat.comImmunityBio Target of Unusually High Options Trading (NASDAQ:IBRX)ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock traders bought 23,649 call options on the stock. This represents an increase of approximately 308% compared to the average volume of 5,801 call options.April 23, 2024 | seekingalpha.comImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer BattleApril 23, 2024 | msn.comBiggest stock movers today: IBRX, NVS, and moreApril 23, 2024 | msn.comImmunityBio stock jumps as FDA clears bladder cancer therapyApril 22, 2024 | businesswire.comImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder CancerApril 22, 2024 | reuters.comU.S. FDA approves ImmunityBio's bladder cancer therapyApril 22, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 4% ImmunityBio (NASDAQ:IBRX) Shares Down 4%April 19, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Up 4.5%ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.5%April 17, 2024 | finance.yahoo.comImmunityBio, Inc. (IBRX) Stock Historical Prices & Data - Yahoo FinanceApril 13, 2024 | marketbeat.comVanguard Group Inc. Increases Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)Vanguard Group Inc. raised its position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 42.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,675,687 shares of the company's stock after acquiring an additional 4April 12, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Down 8.1%ImmunityBio (NASDAQ:IBRX) Stock Price Down 8.1%April 11, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Up 3.7%ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.7%April 3, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 8%ImmunityBio (NASDAQ:IBRX) Shares Up 8%April 1, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 6.7% ImmunityBio (NASDAQ:IBRX) Shares Down 6.7%March 28, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 6.2%ImmunityBio (NASDAQ:IBRX) Trading 6.2% HigherMarch 25, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL)March 25, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Down 5.1%ImmunityBio (NASDAQ:IBRX) Shares Down 5.1%March 25, 2024 | marketbeat.comPiper Sandler Boosts ImmunityBio (NASDAQ:IBRX) Price Target to $5.00Piper Sandler lifted their price target on ImmunityBio from $4.00 to $5.00 and gave the company a "neutral" rating in a research report on Monday.March 22, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Up 8.6%ImmunityBio (NASDAQ:IBRX) Stock Price Up 8.6%March 20, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Sees Unusually-High Trading VolumeImmunityBio (NASDAQ:IBRX) Sees Unusually-High Trading VolumeMarch 19, 2024 | investorplace.comIBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q4 2023March 19, 2024 | benzinga.comImmunityBio: Q4 Earnings InsightsMarch 18, 2024 | marketbeat.comImmunityBio, Inc. (NASDAQ:IBRX) Sees Large Increase in Short InterestImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 29th, there was short interest totalling 51,550,000 shares, a growth of 9.4% from the February 14th total of 47,140,000 shares. Based on an average daily volume of 4,230,000 shares, the short-interest ratio is currently 12.2 days. Currently, 39.4% of the company's shares are sold short.March 17, 2024 | finance.yahoo.comIBRX Jan 2025 1.500 put Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Does this chart look familiar? (Ad)Investors who understand when to get in — and when to get out… Can make a lot of money. Like in the chart, I showed you above… Get all the information here. IBRX Media Mentions By Week IBRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼0.150.58▲Average Medical News Sentiment IBRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼102▲IBRX Articles Average Week Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HALO News CRSP News RVMD News KRYS News PCVX News IMVT News EXEL News SWTX News IOVA News IMCR News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersElon to Transform U.S. Economy? Porter & CompanyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
